HeartBeam Says Device Showed 81.8% vs. 71.4% Specificity Against Standard ECG In Heart Attack Pilot Study, Plans U.S. Pivotal Study In Q1 2027
Share
Why It Matters
HeartBeam's heart device caught more real heart attacks correctly than standard tests did. This is promising, but the real proof comes when they test it on many more patients next year.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.